Evidence map›Paper›PMID 33986805›Full record

ArticleJournal of oncology2021

Discovery and Validation of Circulating EVL mRNA as a Prognostic Biomarker in Pancreatic Cancer.

Yan Du, Kai Yao, Qingbo Feng, Feiyu Mao, Zechang Xin, Peng Xu, Jie Yao

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Yan DuClinic Medical College, Dalian Medical University, Dalian 116000, China.ORCID https://orcid.org/0000-0003-4556-8356
Kai YaoClinic Medical College, Yangzhou University, Yangzhou 225000, China.ORCID https://orcid.org/0000-0002-3581-1730
Qingbo FengDepartment of Liver Surgery, West China Hospital Sichuan University, Chengdu 610000, China.
Feiyu MaoClinic Medical College, Yangzhou University, Yangzhou 225000, China.
Zechang XinClinic Medical College, Dalian Medical University, Dalian 116000, China.
Peng XuDepartment of Hepatobiliary and Pancreatic Surgery, Northern Jiangsu People's Hospital, Clinic Medical College, Yangzhou University, Yangzhou 225000, China.
Jie YaoClinic Medical College, Yangzhou University, Yangzhou 225000, China.ORCID https://orcid.org/0000-0001-5447-893X
Dalian Medical University · CNNorthern Jiangsu People's Hospital · CNYangzhou University · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCirculating plasma mRNAs can be analyzed to identify putative cancer biomarkers. This study was conducted in an effort to detect plasma mRNA biomarkers capable of predicting pancreatic cancer (PACA) patient prognosis.

resultsIn total, three prognostic differentially expressed genes were identified in PACA patient plasma samples, including SMAP2, PTPN6, and EVL (Ena/VASP-like). Plasma EVL levels were confirmed via qPCR to be correlated with tumor pathology (

conclusionWe found that PACA is associated with the downregulation of plasma EVL mRNA levels, indicating that this mRNA may be a viable biomarker associated with patient prognosis.

Identifiers

PMID33986805
PMCPMC8079208
OpenAlexW3156994896

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.